[{"id":"36b25a6e-d1bc-4c39-aec7-9e1f51d0310f","acronym":"ZOLAR","url":"https://clinicaltrials.gov/study/NCT06537596","created_at":"2025-02-26T09:09:12.436Z","updated_at":"2025-02-26T09:09:12.436Z","phase":"Phase 1","brief_title":"89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT06537596 - ZOLAR","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","biomarkers":" PDGFRA","pipe":" | ","alterations":" FOLR1 expression","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lartruvo (olaratumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-12-19"},{"id":"b98e6264-8abc-4bbb-8df4-bbdb8b6e48ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT00913835","created_at":"2021-01-18T03:31:57.820Z","updated_at":"2024-07-02T16:36:55.203Z","phase":"Phase 2","brief_title":"A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer","source_id_and_acronym":"NCT00913835","lead_sponsor":"Eli Lilly and Company","biomarkers":" PDGFRA • MUC16","pipe":" | ","alterations":" PDGFRA expression","tags":["PDGFRA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lartruvo (olaratumab) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 10/01/2011","primary_completion_date":" 10/01/2011","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2019-09-26"},{"id":"eab05140-fe2a-4860-ab08-5fee149e1590","acronym":"","url":"https://clinicaltrials.gov/study/NCT01204710","created_at":"2021-01-18T04:49:41.981Z","updated_at":"2024-07-02T16:36:55.379Z","phase":"Phase 2","brief_title":"A Study of Olaratumab (IMC-3G3) in Prostate Cancer","source_id_and_acronym":"NCT01204710","lead_sponsor":"Eli Lilly and Company","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA expression","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • mitoxantrone • Lartruvo (olaratumab)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 10/01/2013","study_completion_date":" 10/01/2013","last_update_posted":"2019-09-20"},{"id":"68ee80d7-4df8-4d6d-b5f5-3f61a898eb3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02783599","created_at":"2021-01-18T13:39:19.516Z","updated_at":"2024-07-02T16:36:57.053Z","phase":"Phase 1b","brief_title":"A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT02783599","lead_sponsor":"Eli Lilly and Company","biomarkers":" PDGFRA • PDGFC","pipe":" | ","alterations":" PDGFRA expression","tags":["PDGFRA • PDGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Lartruvo (olaratumab)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 10/11/2016","start_date":" 10/11/2016","primary_txt":" Primary completion: 07/05/2018","primary_completion_date":" 07/05/2018","study_txt":" Completion: 07/05/2018","study_completion_date":" 07/05/2018","last_update_posted":"2019-08-12"}]